Clinical Trial Update: Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining switching to Ziprasidone to address adherence and psychotropic-related weight gain concerns in bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Medication Adherence, Bipolar Disorder | Phase 4 | Status: COMPLETED | Results posted: 2014-04-22